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Summary
Bloom syndrome (BS) is more frequent in the Ashkenazic
Jewish population than in any other. There the predom-
inant mutation, referred to as “blmAsh,” is a 6-bp deletion
and 7-bp insertion at nucleotide position 2281 in the
BLM cDNA. Using a convenient PCR assay, we have
identified blmAsh on 58 of 60 chromosomes transmitted
by Ashkenazic parents to persons with BS. In contrast,
in 91 unrelated non-Ashkenazic persons with BS whom
we examined, blmAsh was identified only in 5, these com-
ing from Spanish-speaking Christian families from the
southwestern United States, Mexico, or El Salvador.
These data, along with haplotype analyses, show that
blmAsh was independently established through a founder
effect in Ashkenazic Jews and in immigrants to formerly
Spanish colonies. This striking observation underscores
the complexity of Jewish history and demonstrates the
importance of migration and genetic drift in the for-
mation of human populations.
Introduction
Bloom syndrome (BS) (MIM 210900) is a rare auto-
somal recessive disorder the major clinical features of
which are short stature, a sun-sensitive facial erythema,
and immunodeficiency (reviewed in German and Ellis
1998). BS somatic cells are hypermutable, a feature de-
tectable at the chromosomal level as increased chro-
mosome breakage and excessive chromatid exchange
and at the biochemical and molecular levels as increased
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mutation at HPRT, HLA, GPA, and repeat-sequence
loci. The consequence of this somatic hypermutability
and hyperrecombinability is an enormous predisposition
to cancer (German 1997). The cancers are at the sites
and of the types that are both common (leukemias, lym-
phomas, and carcinomas) and rare (Wilms tumor, reti-
noblastoma, and glial neoplasms) in the general
population.
In 1995, the BS gene, BLM, was isolated by a posi-
tional cloning strategy, and its gene product was found
to have homology to the RecQ subfamily of DNA heli-
cases (Ellis et al. 1995a). A reduced level of BLM RNA
was detected in certain BS cell lines, and mutations that
cause premature translation termination were found in
10 of the 13 persons with BS who initially were ex-
amined (Ellis et al. 1995a). These observations indicated
that null mutations in BLM are responsible for BS, the
primary biochemical defect being the absence from so-
matic cells of the protein BLM.
BS is more common in the Ashkenazic Jewish popu-
lation than in any other so far examined (German et al.
1977), and the Ashkenazic is the only population in
which a mutation in BLM has been other than extremely
rare. Linkage-disequilibrium analysis has provided
strong evidence that a founder effect is the explanation
for the relatively increased frequency of BS in the Ash-
kenazic Jewish population (Ellis et al. 1994). Moreover,
when BLM was isolated, the founder-effect hypothesis
was supported by the fact that, of the four BS persons
with Ashkenazic ancestry who were studied, each was
homozygous for one and the same mutation—a 6-bp
deletion and 7-bp insertion at nucleotide position 2281
in the BLM cDNA (BLMc.2207–2212delATCTGA-
insTAGATTC)—amutation that we refer to as “blmAsh.”
This mutation is carried by 1 of every 107 Ashkenazic
Jews in New York City (Li et al. 1998).
In the present study, we analyzed the BLM gene for
blmAsh in persons with BS, testing DNAs available
through the Bloom’s Syndrome Registry (German and
Passarge 1989). We found, as expected, that blmAsh was
present on 58 of the 60 chromosomes examined in per-
sons with BS who were of Ashkenazic ancestry. Re-
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Table 1
blmAsh in Persons with BS, in Families in Which One or Both
Parents Are Ashkenazic Jews
ANCESTRY OF PARENTSa
NO. OF blmAsh ALLELES/
NO. OF CHROMOSOMES
Ashkenazic Non-Ashkenazic
Ashkenazic (27)b 51/53 0/0
Ashkenazic-American (5)c 5/5 5/0
Ashkenazic-Sephardic (2)d 2/2 1/2
Total (34) 58/60 1/7
NOTE.—All affected families were unrelated, except for one inwhich
two persons with BS had mothers who were first cousins.
a No. of persons with BS is indicated in parentheses.
b In one family, the parents are first cousins; therefore, the blmAsh
chromosomes in this family were counted only once. Two personswith
BS were compound heterozygotes; one mutant allele was blmAsh, and
the other has yet to be identified (see text).
c In each family, one parent is Ashkenazic Jewish, and the other is
American of mixed European but non-Jewish ancestry. In all of these
families, blmAsh was heterozygous in the affected person, being trans-
mitted by the Ashkenazic parent.
d In each family, one parent has Ashkenazic ancestry, and the other
has Sephardic ancestry (see text). In one family, blmAsh was compound
heterozygous in the affected person, being transmitted by the Ash-
kenazic parent. In the other family, blmAsh was homozygous, being
transmitted by both the Ashkenazic parent and the Sephardic parent.
markably, however, we also found blmAsh in five non-
Jewish persons with BS. Each of these lives in the Amer-
icas and has a Spanish-speaking Catholic family that has
resided in the southwestern United States, Mexico, or El
Salvador for many generations. Two of the five families
can trace their ancestry to Spain. Molecular analysis re-
vealed that the blmAsh chromosomes from both Ashke-
nazic and non-Ashkenazic persons carry the same or
related haplotypes. Together, these results, for reasons
that will be given, suggest that blmAsh is present not only
in the Ashkenazic population but also in descendents of
a person who several centuries ago emigrated from Spain
to New Spain and who most likely was a Sephardic Jew.
Subjects, Material, and Methods
Subjects and DNA Samples
The Bloom’s Syndrome Registry was the source of the
biological specimens analyzed. The registry contains
clinical and genetic information from 198 persons with
BS, including a cohort of 169 persons comprising es-
sentially all of the persons in whom BS was diagnosed
before 1991. Only persons with bona fide clinical BS
have been registered, and almost all had the diagnosis
confirmed cytogenetically. The registry has obtained and
preserved biological specimens from affected families as
they have become available: lymphoblastoid cell lines
established from blood lymphocytes, fibroblast cell lines
established from skin biopsies or surgical specimens,
cryopreserved or fresh blood or components of blood,
and fixed and paraffin-embedded pathology specimens.
Genomic DNA was prepared from all persons with BS
and from those of their parents from whom a biological
sample was available to the registry: 139 persons with
BS, representing 125 unrelated families, and 164 parents
available from 91 of these families. In certain cases,
DNAs were prepared from more than one source.
The “BS/Ashkenazic” population was composed of
DNA samples from 27 unrelated persons with BS (with
one exception; see note to table 1), each of whose parents
were Ashkenazic Jewish; DNA samples were available
from 42 of their parents. An additional seven DNA sam-
ples were available from persons with BS who had a
single Ashkenazic parent; DNA samples were available
from 11 of their parents, and 6 of these samples were
from the Ashkenazic parent. In two of these “half”-
Ashkenazic families, Sephardic ancestry was recorded:
In one family, the father of BS sibs 107(MyAsa) and
163(ViAsa) was a Bulgarian Jew both of whose parents
were Sephardic Jewish. In the other family, the maternal
grandfather of 126(BrNad) was a Sephardic Jew, and
the maternal grandmother was an Egyptian Jew. As a
control for the BS/Ashkenazic population, a sample des-
ignated the “non–BS/Ashkenazic” population was ob-
tained that consisted of cryopreserved samples from 50
normal Ashkenazic Jewish men who had been partici-
pants in an unrelated epidemiological study conducted
earlier at the New York Blood Center.
The “BS/non-Ashkenazic” population was composed
of DNAs from 91 unrelated persons with BS, neither of
whose parents were Ashkenazic Jewish; DNAs were
available for testing, when appropriate, from 111 of
their parents. The ancestry of the parents of these per-
sons is recorded in the registry. Of particular interest
here were the seven families that came from the south-
western United States, Mexico, and El Salvador. As a
control for the BS/non-Ashkenazic population, a sample
designated the “non-BS/non-Ashkenazic” population
was examined, which consisted of DNAs from 122
grandparents of families included in the Centre d’Etude
du Polymorphism Humain (CEPH) reference panel.
DNAs were prepared as described elsewhere (Ellis et al.
1995b).
Testing for blmAsh
The blmAsh mutation introduced a BstNI restriction-
enzyme site into BLM. Chromosomes carrying the
mutation contain the BstNI site, whereas other chro-
mosomes do not (Straughen et al. 1998). PCR was per-
formed by use of genomic DNA (50–250 ng/reaction)
and oligonucleotide primers flanking the site of the
blmAsh mutation, as described elsewhere (Li et al. 1998;
Straughen et al. 1998). PCR products were digested with
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Figure 1 Order and physical location of the seven polymorphic markers and one mutation examined (see Straughen et al. 1996). The
orientation of the genomic segment relative to the centromere (circle) was determined by analysis of recombinant chromosomes that were
detected in BS families (German et al. 1994; Ellis et al. 1995b). The physical distances (in kb) between loci is shown under the line that represents
the genomic sequences.
BstNI, according to the manufacturer’s instructions,
and the products were separated by agarose-gel
electrophoresis.
Haplotype Analysis
The polymorphic microsatellite loci D15S996,
D15S1108, D15S127, FES, D15S158, and IP15M9
were selected for genotyping because they are genetically
linked to and physically associated with BLM (fig. 1)
and are efficiently polymorphic. Genotypes at these six
loci were determined by PCR. Information on oligonu-
cleotide primers, expected allele sizes, distribution of al-
lele frequencies, and conditions for PCR amplification
have been described elsewhere (German et al. 1994; Dib
et al. 1996; Straughen et al. 1996).
Haplotypes of Ashkenazic blmAsh chromosomes and
of Ashkenazic non-blmAsh chromosomes were con-
structed on the basis of genetic information from the
available parents. To construct haplotypes, we assumed
that no recombination had occurred between BLM and
the polymorphic markers in the parental meioses that
immediately preceded formation of the BS zygote. This
will hold true in most cases because crossing-over in the
interval between BLM and the outside flanking markers
(D15S996 and IP15M9) is expected to occur at a fre-
quency of !1%, the six polymorphic microsatellite loci
under study being in a 1.3-cM interval (Straughen et
al. 1996). The parental origin of each allele was deter-
mined unambiguously except when the parents (or par-
ent, if only one was available) and the person with BS
had the same heterozygous genotype, the situation at a
single locus in five families. In two of these cases, the
ambiguity was resolved without bias: in one case, a sib
who inherited the maternal blmAsh chromosome was ex-
amined, for comparison; in the other, a lymphoblastoid
cell line from the affected person was available, the cells
of which by chance had lost the maternal chromosome
15. The ambiguities in the three other cases were re-
solved by constructing the two possible haplotypes and
selecting the one that increased the numbers of the more
common haplotypes (see Results).
A Polymorphism within BLM
Detected during the initial mutational analysis of
BLM was a nucleotide substitution, TrA at position
3699 in the BLM cDNA (BLMc.3625TrA), a change
that causes an amino acid substitution, SrT at residue
1209. To examine the BLM3699 polymorphism in our
DNA samples, we amplified the genomic sequences
flanking the site of the polymorphism, employing the
primer pair E19A5′ (CCTGTATGGTACAAGTGCA-
CAT) and E19B3′ (CGTGTCTAATTATCCGGCTTTC)
to generate a fragment of 301 bp. The site of the poly-
morphism can be digested with the restriction enzyme
Tsp45I: When the T base is present, digestion produces
fragments of 229 bp and 72 bp; when the A base is
present, digestion produces fragments of 121 bp, 108
bp, and 72 bp (the 72-bp fragment being present in both
digestions).
Results
blmAsh in BS/Ashkenazic Families
The blmAsh mutation was detected by PCR analysis of
genomic DNA. Of the 27 unrelated BS/Ashkenazic per-
sons examined, 25 were homozygous for blmAsh, and 2
were compound heterozygotes (table 1). Of the 47 avail-
able parents of the BS/Ashkenazic persons, 45 trans-
mitted the blmAsh allele to the person with BS, and 2
transmitted yet-to-be-defined mutant alleles present in
the 2 aforementioned compound heterozygotes. Of the
seven persons with BS who had only a single Ashkenazic
parent, all were compound heterozygotes for blmAsh. Of
the six available Ashkenazic parents of the “half”-BS/
Ashkenazic persons, all transmitted the blmAsh allele. Al-
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Table 2
blmAsh Chromosomes in 91 Unrelated Persons with BS Who Were
Born into Non-Ashkenazic Families
ANCESTRY (NO. OF PERSONS)
NO. OF CHROMOSOMES
Non-
Ashkenazica blmAsh
American, European ancestry (31) 56 0
German (8) 15 0
Italian (8) 11 0
Japanese (8) 13 0
Dutch and Belgian (6) 12 0
American, African ancestry (4) 6 0
Brazilian (4) 8 0
American, Spanish ancestry (4)b 3 4
Turkish (4) 6 0
El Salvadoran (3)c 3 3
French Canadian (2) 3 0
Argentinean (1) 2 0
Australian, European ancestry (1) 2 0
Ecuadoran (1) 2 0
English (1) 1 0
Indian, Bombay region (1) 2 0
Lebanese (1) 1 0
Persian Jewish (1) 1 0
Portuguese (1) 2 0
Spanish (1) 1 0
a Calculated as follows: in the families in which parental consan-
guinity was known, only one chromosome mutated at BLM was
counted; to this was added the number of mutated chromosomes from
the families lacking known parental consanguinity.
b Parents of the persons with BS were born in Mexico (6), southern
Colorado (2), Utah (1), and New Mexico (1). In one of the two Mex-
ican families and in the one Colorado family, blmAsh was homozygous
in the person with BS. Parental consanguinity was recorded in the
Colorado family but not in the Mexican family. In the New Mexican
family, the person with BS was a blmAsh compound heterozygote. In
the second Mexican family, blmAsh was not present. As in footnote
“a,” the blmAsh chromosome in the consanguineous family is counted
as a single chromosome
c In one family, blmAsh was homozygous in the person with BS; in
another family, it was compound heterozygous; in a third, it was ab-
sent. In one family listed as being El Salvadoran, the mother, who
carried blmAsh, was from El Salvador, and the father, who carried a
different mutation at BLM, was from Ecuador. Consanguinity was not
recorded in any of these three families.
together, the blmAsh allele was found on 58 of the 60 BS/
Ashkenazic chromosomes examined (table 1).
blmAsh in Non-Ashkenazic Persons
The blmAsh mutation was conspicuously absent from
the several western European populations that histori-
cally have long been in contact with the Ashkenazic pop-
ulation (table 2). Not a single blmAsh chromosome was
detected in 31 non-Jewish North American persons with
BS who were of mixed European ancestry, 8 Germans,
8 Italians, 6 persons of Dutch and Belgian ancestry, and
1 Englishman. In striking contrast, and completely un-
expected, blmAsh was detected in five unrelated persons
whose families came from New Mexico (one family),
southern Colorado (one family), Mexico (one family),
and El Salvador (two families) (see table 2). In three
families, the person with BS was a blmAsh homozygote.
Parental consanguinity can explain the homozygosity in
the Colorado family but was not recorded in the other
two. blmAsh was found in two of the three El Salvadoran
families studied. In one of these families, the person with
BS was a blmAsh homozygote; in this family the parents
denied consanguinity. In the other family, the person
with BS was a blmAsh compound heterozygote; the
mother, who was El Salvadoran, transmitted the blmAsh
allele, whereas the Ecuadoran father transmitted a dif-
ferent BLM mutation to the affected child.
None of these five families in which blmAsh was seg-
regating were aware of Ashkenazic ancestry; instead,
they reported their families to be Christian as far back
as was known, and two of the families reported specif-
ically that their ancestors were from Spain. Spanish has
been spoken for generations in each of the five families.
These observations suggest that the blmAsh mutation in
these families came to the Americas from Spain. If the
blmAsh mutation came from Spain, then it is highly prob-
able that, given the presence of blmAsh in the Ashkenazic
population, the mutation in the Spanish American non-
Jewish families in fact derives from the Sephardic pop-
ulation. None of these families reported Sephardic an-
cestry, except for one that had lived in Jalisco for many
generations and in which the tradition has been passed
down that the patient’s maternal grandmother had
“a Sephardi ancestor.” Consistent with a Sephardic
origin of blmAsh segregating in Spanish Americans,
107(MyAsa), a person with BS who was living in New
York City, inherited a blmAsh mutation from her Bul-
garian father, a Sephardic Jew (table 1). Thus, of the
two Sephardic chromosomes mutated at BLM that we
have been able to analyze, one carries blmAsh.
Haplotype Analysis of blmAsh Chromosomes
The molecular nature of the blmAsh mutation suggests
that it arose only once. However, in order to learn
whether the blmAsh chromosomes in the Ashkenazic and
non-Ashkenazic populations were indeed from a com-
mon ancestor, haplotype analysis was performed. In our
earlier study (Ellis et al. 1994), we described a linkage
disequilibrium between BLM, D15S127, and FES in
Ashkenazic Jews with BS. In the present study, we have
determined, in persons with BS who carry blmAsh and in
those of their parents who were available, the genotypes
of six polymorphic microsatellite loci flanking BLM, in-
cluding FES and D15S127 (see Straughen et al. 1996),
and also the genotype of one diallelic locus within BLM,
the BLM3699 polymorphism described above. On the
basis of this information, haplotypes were constructed
from 51 Ashkenazic blmAsh chromosomes (fig. 2). Con-
Figure 2 Haplotypes of 51 Ashkenazic blmAsh chromosomes, 6 non-Ashkenazic blmAsh chromosomes, and 2 Ashkenazic non-blmAsh
chromosomes (determined as described in the text). The identification at the left of each chromosome is taken from the Bloom’s Syndrome
Registry’s designation of the person with BS; the parental origin of each chromosome is indicated: pat  paternal, mat  maternal. Reference
to all except the most recently accessioned persons can be found in one of the reports from the registry, which have been made serially since
1977 (see German and Passarge 1989). The genetic history of each registered person whose chromosomes are represented here as Ashkenazic
indicates that each of his or her chromosomes was transmitted from a parent who was an Ashkenazic Jew. The genetic history of persons whose
chromosomes are represented here as non-Ashkenazic indicates that each chromosome was transmitted in this case by a Spanish-speaking
Christian person whose families have dwelt for many generations in the southwestern United States, Mexico, or El Salvador. The eight loci
(boldface) are arrayed in the order that they assume in the human genome (fig. 1). The alleles present on the founder’s haplotype, named across
the top, are indicated by the thicker portion of each line; alleles not present on the founder’s haplotype are indicated by the thinner portions
of each line, and there the allele present on each is indicated. To the right of each haplotype is indicated the D15S127 allele (145 bp or 147
bp) that is present on that chromosome.
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Table 3
BLM3699 Polymorphism in Unrelated Ashkenazic and Non-
Ashkenazic Persons
POPULATION (NO. OF PERSONS)
NO. OF CHROMOSOMES
CARRYING
A Base T Base
BS/Ashkenazic (27)a 51 2
BS/Ashkenazic-American (5)b 5 5
BS/Ashkenazic-Sephardic (2)c 3 1
BS/non-Ashkenazic (87)d 7 144
Non-BS/Ashkenazic (50)e 1 99
Non-BS/non-Ashkenazic (117) 0 234
a See footnote “b” to table 1.
b See footnote “c” to table 1. The A base was always inherited from
the Ashkenazic parents.
c See footnote “d” to table 1. Four persons were not typed at
BLM3699. The A base was inherited from each of the Ashkenazic
parents and by one of the Sephardic parents, the Bulgarian Jew referred
to in the text.
d See footnote “a” to table 2. The A base was present only in persons
who carried blmAsh. In the Colorado person with BS whose parents
were cousins, the chromosome carrying the A base was counted only
once.
e The one non-BS/Ashkenazic person sampled who carries the A
base is also a carrier of blmAsh.
sistent with the linkage disequilibrium described earlier,
a single allele predominates at each locus, thus forming
a predominant haplotype, with one exception (see be-
low). Twenty-seven of the 51 chromosomes carry this
haplotype—the founder’s haplotype—which very likely
represents the chromosome on which the blmAsh muta-
tion arose.
The exception just mentioned is at polymorphic locus
D15S127. There, two alleles are present at roughly equal
frequencies (fig. 2). On the Ashkenazic blmAsh chromo-
somes, the 147-bp allele is present on 25 chromosomes,
and the 145-bp allele is present on 23 chromosomes; 3
chromosomes carry neither of these two alleles. Of the
chromosomes carrying the founder’s haplotype, the 147-
bp allele is present on 15, and the 145-bp allele is present
on 12. The founder carried a chromosome that had one
of these two alleles atD15S127; the other allele probably
arose from this allele by a mutational event that added
or subtracted a single dinucleotide in the CA-repeat ar-
ray constituting the polymorphic segment at D15S127.
The haplotype data suggest that the mutational event is
relatively frequent, such that, over time, neither allele
predominates. Thus, for the haplotype analysis pre-
sented here, we have combined the chromosomes to rep-
resent the founder’s haplotype.
As stated above, 28 of the 51 Ashkenazic blmAsh chro-
mosomes carry the founder’s haplotype. On the re-
maining 23 chromosomes, there are 18 different hap-
lotypes; however, 22 of these 23 chromosomes carry
some portion of the founder’s haplotype at a minimum
of three contiguous loci (fig. 2). The one remaining chro-
mosome, the one transmitted by the father of 14(LeSi),
carries only a single allele represented in the founder’s
haplotype; but, important to the present argument, it is
the one in the BLM gene itself (see below). These 18
different haplotypes are derived from the founder’s hap-
lotype either by recombinational events between the
BLM gene and the loci flanking it, by mutational events
at the marker loci themselves, or by both.
Haplotypes could be constructed from six of the seven
non-Ashkenazic blmAsh chromosomes identified in the
Spanish Americans with BS, and a striking pattern
emerged (fig. 2). First, only two haplotypes were
found—namely, the founder’s haplotype and a haplo-
type that carries an 87-bp allele at D15S158, instead of
the founder’s 93-bp allele. Second, atD15S127, only the
145-bp allele is present, in contrast to the Ashkenazic
blmAsh chromosomes that exhibit both the 145-bp and
147-bp alleles. The data indicate that blmAsh is present
in the Spanish American families through a founder
effect.
Analysis of the BLM3699 Polymorphism
One allele of the founder’s haplotype is present on all
the blmAsh chromosomes examined (table 3). The poly-
morphism is a TrA nucleotide substitution at bp 3699
of the BLM cDNA. Although the A base is present on
all blmAsh chromosomes, we have not found it on any
other chromosome tested. The one person in the non-
BS/Ashkenazic population who carried the A base
proved also to be a carrier of blmAsh!
The BS/Ashkenazic Non-blmAsh Chromosomes
As mentioned above, two BS/Ashkenazic chromo-
somes were identified in which blmAsh is not the BLM
mutation. These two chromosomes also fail to carry
more than two alleles of the founder’s haplotype, and,
specifically, they do not carry the BLM3699 A base (see
fig. 2) Thus, these two chromosomes did not come from
the blmAsh founder. However, because the two chro-
mosomes have an identical haplotype, we conclude that
they too are derived from a founder individual and
thereby carry the same mutation at BLM.
Discussion
The data presented here demonstrate conclusively that
the blmAsh mutation in the BS/Ashkenazic population is
derived from a founder individual. Therefore, chromo-
somes carrying the blmAsh mutation have increased in
frequency in the Ashkenazic population by random ge-
netic drift. Linkage disequilibrium between BLM, FES,
and D15S127, detected in Ashkenzic Jews with BS, had
earlier suggested the same conclusion (Ellis et al. 1994).
Moreover, when BLM was cloned, the blmAsh mutation
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was found in all of the four Ashkenazic persons with
BS who were examined (Ellis et al. 1995a). The alter-
native view—that a heterozygote advantage caused an
increase in the gene frequency of blmAsh in the Ashke-
nazic population—seems unlikely, for two reasons: (1)
The frequency of heterozygotes in the Ashkenazic pop-
ulation is only 1/107 (Li et al. 1998), and (2) a single
mutation—namely, blmAsh—predominates in the Ash-
kenazic population, rather than several common mu-
tations, which is the situation for Tay-Sachs andGaucher
diseases (Eng et al. 1997; Kronn et al. 1998).
In the present study, we have tested directly for the
blmAsh mutation in all persons with BS fromwhomDNA
samples were available, and we have found, not sur-
prisingly, that 58 of the 60 BS/Ashkenazic chromosomes
examined carried blmAsh. Two Ashkenazic Jews with BS
were identified who carry a mutation different from
blmAsh. The nonblmAsh mutation could have either en-
tered the Ashkenazic population from another popula-
tion by admixture or arisen as a new mutation in BLM
in the Ashkenazic population.
It was surprising, however, to find blmAsh segregating
in present-day Christian families of Spanish decent who
for generations have dwelt in the southwestern United
States, Mexico, or El Salvador. These Spanish American
blmAsh chromosomes have haplotypes that also are pres-
ent on the Ashkenazic blmAsh chromosomes, indicating
that they are derived from a common ancestor. However,
only two different haplotypes were found on the six
Spanish American blmAsh chromosomes, and both of
these contained just the 145-bp allele atD15S127.These
data suggest that blmAsh is present in certain Spanish
American families through a founder effect that occurred
more recently than, and in a place different from the
origin of, the founder effect responsible for the relatively
high frequency of blmAsh in the Ashkenazic population.
The data on the BLM3699 polymorphism, a diallelic
DNA variant, are particularly strong evidence for a sin-
gle origin of the blmAsh mutation, and they support the
hypothesis that the blmAsh chromosomes discovered in
both the Ashkenazic population and the non-Ashkenazic
Spanish American population ultimately trace to a com-
mon ancestor. They also raise the possibility that, even
today, a population exists in which the A base is seg-
regating, but on a chromosome that is not mutant at
BLM. Such a population could be the one in which the
blmAsh mutation arose.
How can blmAsh in American non-Jewish persons be
explained? One improbable explanation is that a recent
ancestor in each of these five Spanish-speakingAmerican
families is an Ashkenazic Jew who carried blmAsh. Very
few Ashkenazic Jews settled in the southwestern United
States, Mexico, or El Salvador prior to the 1880s, and
most present-day descendants of such Ashkenazic Jews
would be expected to consider themselves Ashkenazic
(Rochlin and Rochlin 1986; Barnavi 1992). Two of the
five families were able to provide reliable information
concerning their recent generations, and there was no
mention of Ashkenazic ancestry. For these reasons, we
do not favor the idea of a recent Ashkenazic ancestor
for the five families.
Could Spanish American blmAsh have come from an
Ashkenazic Jew who immigrated either to Spain or to
the Spanish colonies during a preceding century? An-
swering this question depends on knowing when and
where the blmAsh founder effect occurred in the Ashke-
nazic Jewish population. This population began in me-
dieval Europe during the Carolingian period; it grew in
number, from ∼5,000 at the end of the first millennium,
to 20,000, at the end of the 11th century; and it was
forced to move, in piecemeal fashion, from England,
northern France, and the Rhineland during the 13th and
14th centuries. Many moved to eastern Europe during
that period, thereby establishing Polish Jewry in the ar-
eas that presently are Poland, Lithuania, Belarus, and
Ukraine. The blmAsh mutation is increased in frequency
in Jewish persons who trace their ancestry to these east-
ern European regions (German et al. 1977; Li et al.
1998); however, the event that led to the relatively in-
creased frequency of blmAsh in the Ashkenazim cannot
be dated with certainty to either their eastward migra-
tion or the millennial formation of the Ashkenazic pop-
ulation in western Europe. It is therefore difficult to
know whether blmAsh came to the Americas via eastern
Europe, whether Ashkenazic admixture with the Se-
phardic population prior to the establishment of Polish
Jewry could have brought blmAsh from northern Europe
to Spain, or whether, in the absence of gene flow from
the Ashkenazic population, the blmAsh mutation was
present in the Sephardic population in Spain.
All of these explanations are possible. After the Ex-
pulsion Decree made by Ferdinand and Isabella in 1492,
many Sephardic Jews migrated to parts of the New
World that were held by Spain. Eventually, however, the
Inquisition became active in repressing Judaism there,
as it had in Spain (Gerber 1992). Thus, it is conceivable
that a 16th- or 17th-century Sephardic immigrant to the
New World who had converted to Christianity and who
carried blmAsh could have been the ancestor of Spanish
American Christians carrying blmAsh chromosomes to-
day. A similar explanation could be given for the founder
effect that has been detected in persons of Spanish an-
cestry who have Laron syndrome and who are now liv-
ing in Ecuador, all of whom carry the E180 splice mu-
tation (Berg et al. 1994). The E180 splice mutation was
also found in an Israeli Jew with Moroccan ancestry,
suggesting a Sephardic ancestor to both Ecuadoran and
Moroccan persons who carry the E180 splice mutation.
In the example from BS, the Sephardic Jew who brought
blmAsh to the New World could have inherited blmAsh
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from an Ashkenazic Jew in his ancestry, but, alterna-
tively, he could have inherited blmAsh from a Jewish per-
son who was ancestral to both the Ashkenazic and Se-
phardic populations.
Our finding of blmAsh in the father of 107(MyAsa), a
Bulgarian Sephardic Jew, also could be accounted for by
either of two explanations given above; that is, it could
be due to either Ashkenazic-Sephardic admixture during
the years of the Ottoman Empire or to the massive im-
migration of Sephardic Jews to Turkey during the 16th
century.
In summary, screening for blmAsh in families ascer-
tained through BS has uncovered a fascinating historical-
genetic mystery. The blmAsh mutation, common among
persons of Ashkenazic ancestry, has been found to be
segregating in Spanish-speaking Christian BS families
who for many generations have dwelt in the south-
western United States, Mexico, or El Salvador, at least
some of whom can trace their ancestry to Spain. blmAsh
was not detected in any other non-Jewish population.
Many different historical events could explain this un-
expected observation. What can be said with certainty
is that the blmAsh mutation is present in these two dif-
ferent populations as a result of two independent foun-
der effects. The results underscore both the complexity
of historical events that surround the formation of dif-
ferent human populations and the effects of that com-
plexity on present-day genetic studies. They also em-
phasize the central role of migration and founder effect
in the genetics of human populations.
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